Expression and clinical significance of CCR2, CCL2 and Foxp3 in colon cancer

doi:10.3877/cma.j.issn.2095-7157.2023.01.014

Abstract

Abstract:

Objective

To investigate the expression of CCR2, CCL2 and Foxp3 in colon cancer and its relationship with clinicopathological features.

Methods

120 cases of colon cancer from August 2020 to March 2021 were collected from Chinese Traditional Medical Hospital of Jiangsu Province, and the expression of CCR2, CCL2 and Foxp3 was detected by immunohistochemistry.

Results

The positive rate of CCR2, CCL2 and Foxp3 in colon cancer tissues was much higher than that in normal tissues (P< 0.05). The expression of CCR2, CCL2 and Foxp3 was significantly correlated with lymph node metastasis, depth of tumor invasion, degree of differentiation and clinical tumor stage (P< 0.05), and the expression of the three was positively correlated with each other (P< 0.001). Among the three, CCR2 had the highest accuracy in diagnosing lymph node metastasis of colon cancer and was also superior to that of enhanced CT.

Conclusion

CCR2/CCL2 axis and Foxp3 are closely related to lymph node metastasis of colon cancer. Detecting the expression of CCR2/CCL2 axis and Foxp3 in colon cancer tissue is beneficial to predicting lymph node metastasis, evaluating prognosis and guiding postoperative treatment.

Key words: Colorectal cancer, CCR2, CCL2, Foxp3, Immunohistochemistry

Xiaoyun Lu, Shuhan Yu, Zeyu Wu, Qide Zhang, Peiyao Wu. Expression and clinical significance of CCR2, CCL2 and Foxp3 in colon cancer[J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2023, 10(01): 52-56.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhwcnjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-7157.2023.01.014

https://zhwcnjdzzz.cma-cmc.com.cn/EN/Y2023/V10/I01/52

Figures/Tables 10

References 18

[1]	Sung H，Ferlay J，Siegel RL，et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin，2021，71(3): 209-249.
[2]	Gallo G，Vescio G，Paola GD，et al.Therapeutic Targets and Tumor Microenvironment in Colorectal Cancer[J].J Clin Med，2021，10(11)：2295 -2312.
[3]	Kiguchi N，Kobayashi Y，Kishioka S．Chemokines and cytokines in neuroinflammation leading to neuropathic pain[J].Curr Opin Pharmacol, 2012，12(1)：55-61.
[4]	Gao YJ，Zhang L，Ji RR.Spinal injection of TNF--activated astrocytes produces persistent pare symptom mechanical allodynia by releasing monocyte chemoattractant protein-l[J].Glia，2010，58(15)：187l-1880.
[5]	Conductier G，Blondeau N，Guyon A，et a1.The role of monocyte chemoattractant protein MCPl/CCL2 in neuroinflammatory diseases[J].J Neuroimmunol，2010, 224(1-2): 93-100.
[6]	Lim SY，Yuzhalin AE，Gordon-Weeks AN，et al.Targeting the CCL2-CCR2 signaling axis in cancer metastasis[J].Oncotarget，2016, 7(19): 28697-28710.
[7]	Gallo G，Sena G，Vescio G，et al.The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review[J].Ann Ital Chir，2019，90 (2)：127-137.
[8]	O′Connell JB，Maggard MA，Ko CY.Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging[J].J Natl Cancer Inst，2004，96(19)：1420-1425.
[9]	Chaffer CL，Weinberg RA.A perspective on Cancer Cell Metastasis[J]. Science，2011, 331 (6024)：1559-1564.
[10]	Zeng Y，Wang XW，Yin BJ, et al.Role of the stromal cell derived factor-1/CXC chemokine receptor 4 axis in the invasion and metastasis of lung cancer and mechanism[J].J Thorac Dis，2017，9(12)：4947-4959.
[11]	Bazzani L，Donnini S，Finetti F，et al.PGE2/EP3/SRC signaling induces EGFR nuclear translocation and growth through EGFR ligands release in lung adenocarcinoma cells[J].Oncotarget，2017，8：31270- 31287.
[12]	Han KQ，He XQ，Ma MY，et al.Inflammatory microenvironment and expression of chemokines in hepatocellular carcinoma[J].World J Gastroenterol，2015，21(16)：4864-4874.
[13]	Boulter Luke，Bullock Esme，Mabruk Zeanap，et al.The fibrotic and immune microenvironments as targetable drivers of metastasis[J].Br J Cancer，2021，124(1): 27-36.
[14]	Hu H，Sun L，Guo C，et al.Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis[J].Clin Cancer Res, 2009，15(17): 5485-5493.
[15]	Danese S，Mantovani A．Inflammatory bowel disease and intestinal cancer：a paradigm of the Yin-Yang interplay between inflammation and cancer[J].Oncogene，2010，29(23)：3313-3323.
[16]	Bailey C，Negus R，Morris A，et al.Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer[J].Clin Exp Metastasis，2007, 24(2)：121-130.
[17]	Charbonnier LM，Cui Y，Stephen-Victor E，et al.Functional reprogramming of regulatory T cells in the absence of Foxp3[J].Nat Immunol，2019，20(9)：1208-1219.
[18]	Shou Jiafeng，Zhang Zhigang，Lai Yucheng，et al.Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs: a systematic review and meta-analysis[J].BMC Cancer，2016，26(16): 687-694.

组别	例数	CCR2的表达		阳性表达率(%)	CCL2的表达		阳性表达率(%)	Foxp3的表达		阳性表达率(%)
组别	例数	阳性	阴性	阳性表达率(%)	阳性	阴性	阳性表达率(%)	阳性	阴性	阳性表达率(%)
结肠癌组	120	69	51	57.5	55	65	45.8	72	48	60.0
癌旁正常组	40	6	34	15.0	4	36	10.0	7	33	17.5
χ²值				21.760			16.549			21.678
P值				<0.001			<0.001			<0.001

组别	例数	CCR2的表达		阳性表达率(%)	CCL2的表达		阳性表达率(%)	Foxp3的表达		阳性表达率(%)
组别	例数	阳性	阴性	阳性表达率(%)	阳性	阴性	阳性表达率(%)	阳性	阴性	阳性表达率(%)
结肠癌组	120	69	51	57.5	55	65	45.8	72	48	60.0
癌旁正常组	40	6	34	15.0	4	36	10.0	7	33	17.5
χ²值				21.760			16.549			21.678
P值				<0.001			<0.001			<0.001

临床因素	例数	CCR2阳性表达			CCL2阳性表达			Foxp3阳性表达
临床因素	例数	例	率(%)	P值	例	率(%)	P值	例	率(%)	P值
年龄(岁)
≥60	87	51	58.6	0.687	41	47.1	0.644	54	62.1	0.453
<60	33	18	54.5		14	42.4		18	54.5
性别
男	74	46	62.2	0.190	36	48.6	0.432	45	60.8	0.818
女	46	23	50.0		19	41.3		27	58.7
肿瘤大小(cm)
≥5	47	28	59.6	0.712	22	46.8	0.863	29	61.7	0.760
<5	73	41	56.2		33	45.2		43	58.9
TNM分期
Ⅰ+Ⅱ期	48	15	31.3	<0.001	13	27.0	0.001	13	27.1	<0.001
Ⅲ+Ⅳ期	72	54	75.0		42	58.3		59	81.9
分化程度
中高分化	86	41	47.7	0.001	29	33.7	<0.001	43	50.0	<0.001
低分化	34	28	82.4		26	76.5		29	85.3
淋巴结转移
无	52	8	15.4	<0.001	12	23.1	<0.001	21	40.4	<0.001
有	68	61	89.7		43	63.2		51	75.0
浸润深度
未侵及浆膜	50	13	26.0	<0.001	10	20.0	<0.001	17	34.0	<0.001
侵及浆膜	70	56	80.0		45	64.3		55	78.6

临床因素	例数	CCR2阳性表达			CCL2阳性表达			Foxp3阳性表达
临床因素	例数	例	率(%)	P值	例	率(%)	P值	例	率(%)	P值
年龄(岁)
≥60	87	51	58.6	0.687	41	47.1	0.644	54	62.1	0.453
<60	33	18	54.5		14	42.4		18	54.5
性别
男	74	46	62.2	0.190	36	48.6	0.432	45	60.8	0.818
女	46	23	50.0		19	41.3		27	58.7
肿瘤大小(cm)
≥5	47	28	59.6	0.712	22	46.8	0.863	29	61.7	0.760
<5	73	41	56.2		33	45.2		43	58.9
TNM分期
Ⅰ+Ⅱ期	48	15	31.3	<0.001	13	27.0	0.001	13	27.1	<0.001
Ⅲ+Ⅳ期	72	54	75.0		42	58.3		59	81.9
分化程度
中高分化	86	41	47.7	0.001	29	33.7	<0.001	43	50.0	<0.001
低分化	34	28	82.4		26	76.5		29	85.3
淋巴结转移
无	52	8	15.4	<0.001	12	23.1	<0.001	21	40.4	<0.001
有	68	61	89.7		43	63.2		51	75.0
浸润深度
未侵及浆膜	50	13	26.0	<0.001	10	20.0	<0.001	17	34.0	<0.001
侵及浆膜	70	56	80.0		45	64.3		55	78.6

CCR2	例数	CCL2		r值	P值
CCR2	例数	阳性表达	阴性表达	r值	P值
阳性表达	69	46	23	0.437	<0.001
阴性表达	51	9	42

Please choose a citation manager

Content to export